2024 Fall Conference | Industry Therapeutic Update from Eli Lilly: Explore a New Therapy for Early Symptomatic Alzheimer’s Disease

Date Saturday 10/26/24

Time 12:00 PM - 01:00 PM PDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology, Aging, Dementia, and Behavioral Neurology

Learning Objectives Listen to a live presentation about the recent efficacy and safety findings of a treatment option for patients with early symptomatic Alzheimer's disease.
This program is sponsored by, and presented on behalf of Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 Fall Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials

Event Timeline
12:00 PM - 01:00 PM PDT	Speaker	Industry Therapeutic Update from Eli Lilly and Company: Explore a New Therapy for Early Symptomatic Alzheimer’s Disease